What Is KPV Peptide and What Does It Do?

KPV peptide is the short Lys-Pro-Val sequence that sits at positions 11-13 of the hormone α-melanocyte-stimulating hormone (α-MSH). Lab studies show this fragment can block NF-κB-driven inflammatory pathways, reduce reactive oxygen species and curb cytokine release in cells and animal models. Researchers are testing KPV in gut, skin and liver inflammation, but there are no published human clinical trials yet, and the peptide is not FDA-approved. Under a new 2026 enforcement-discretion policy, state-licensed 503A pharmacies may compound KPV for individual patients if a prescriber writes a patient-specific prescription and all policy conditions are met.

• KPV stands for the amino acids lysine, proline and valine-the last three residues of α-MSH.
• In cell studies, KPV lowered interleukin-1β release and oxidative stress triggered by particulate matter in skin cells (Sung et al., 2025).
• Mouse models of ulcerative colitis improved when KPV was delivered to the colon, even without another drug inside the nanoparticle (Wu et al., 2019).
• The interim FDA policy lets 503A pharmacies compound KPV for patients, but compounded KPV is still not FDA-approved.
• Rx.com plans to offer prescription compounded versions of KPV through U.S.-licensed providers and a licensed 503A pharmacy (coming soon).

KPV peptide is a three-amino-acid fragment of α-MSH

KPV is the minimal C-terminal fragment (positions 11-13) of the 13-amino-acid hormone α-MSH. α-MSH itself is produced in the pituitary and other tissues and is best known for regulating skin pigmentation, appetite and inflammation (Ichiyama et al., 2000). Investigators isolated the Lys-Pro-Val tail after discovering it retained many of α-MSH’s anti-inflammatory traits without the pigment-darkening effect.

Our detailed guide to the peptide compounding policy explains why fragments such as KPV are treated as separate active ingredients under U.S. law.

KPV may interrupt the body’s inflammatory switch

Most lab findings point to KPV blocking the NF-κB pathway, a master regulator that turns on pro-inflammatory genes. In keratinocyte cultures exposed to particulate matter, KPV reduced reactive oxygen species and prevented NF-κB from moving into the nucleus, which in turn lowered IL-1β secretion (Sung et al., 2025). Similar redox-driven NF-κB inhibition has been observed in liver cell models of fat accumulation (Lee et al., 2026).

PepT1 targeting: The peptide transporter PepT1 is over-expressed on inflamed colon cells. KPV’s natural affinity for this transporter lets researchers “hitch-hike” drug-loaded nanoparticles directly into ulcerated tissue (Wu et al., 2019) (Zeng et al., 2017).

Antimicrobial signaling: Early work showed both α-MSH and KPV increased cAMP inside bacteria and yeasts, reducing Staphylococcus aureus colony growth and Candida albicans germ-tube formation (Cutuli et al., 2000). These findings have not yet been confirmed in live animals or humans.

Scientists are testing KPV in gut, skin and liver inflammation

Ulcerative colitis: In DSS-induced colitis mice, colon-targeted KPV nanoparticles improved weight loss, colon length and disease activity scores compared with untreated controls (Wu et al., 2019). A newer oral pro-KPV conjugate accumulated 3.8-fold more in injured colon than free peptide and eased colitis at a 20-fold lower dose (Cheng et al., 2026).

Skin barrier damage: Human keratinocytes exposed to PM10 pollution regained viability and showed lower IL-1β after KPV treatment (Sung et al., 2025).

Fatty liver models: In HepG2 cells overloaded with oleic acid, KPV cut lipid buildup and down-regulated FAS expression by modulating the ROS-PPARγ pathway (Lee et al., 2026).

Sports medicine interest: Fitness forums promote KPV as part of the so-called “Wolverine stack” for recovery, but a 2026 review warned that clinical data on athletic use are virtually nonexistent and potential cardiovascular and metabolic risks are unknown (Coutinho et al., 2026).

Current U.S. regulatory status

No KPV product is FDA-approved. That means there is no commercially manufactured, FDA-reviewed version on the market.

The 2026 interim enforcement discretion policy: In July 2026 the FDA’s Pharmacy Compounding Advisory Committee recommended allowing certain peptides, including KPV, for 503A compounding. HHS later issued an “Interim Access Policy for Compounding Using Certain Peptides.” Under this policy the FDA does not intend to take enforcement action against state-licensed 503A pharmacies and physicians that compound KPV for individual patients, as long as conditions on ingredient quality, manufacturing standards, labeling and safety reporting are met. The policy is not an FDA approval, does not add KPV to the bulks list, has no end date, and states may choose not to follow it.

How prescription KPV could become available

Rx.com plans to offer prescription compounded versions of KPV through U.S.-licensed providers and a licensed 503A pharmacy (coming soon). When the service launches, eligible adults will complete an online health intake, and the provider will decide whether a compounded KPV prescription is appropriate. If prescribed, the medication will be prepared for the individual patient and shipped to their door.

Avoid research-only sellers: Products labeled “research use only” or “not for human use” fall outside the interim policy and are unregulated for purity or sterility. Our guide on how compounded and research peptides differ explains the safety gaps.

For updates on launch timing you can bookmark prescription peptides from Rx.com-the page will list KPV ordering details once live. There is no waitlist or reservation fee.

Potential side effects and unknowns

No human safety trials have been published. The only data come from animals and cell cultures, which cannot predict real-world risks. The 2026 FDA staff review noted the absence of human safety studies for KPV and cited unknowns around systemic absorption, immune reactions and long-term organ effects.

Theoretical risks based on mechanism:

• Immune suppression: Because KPV down-regulates NF-κB, excessive exposure could blunt necessary immune responses to infection.
• Off-target pigmentation changes: While KPV lacks the full α-MSH sequence, downstream melanocortin effects are not completely ruled out.
• Contamination and dosing errors: Research-grade vials have been found mislabeled or adulterated in FDA warning letters for other peptides. Using an inspected 503A pharmacy reduces but does not eliminate these risks.

Until controlled clinical trials report, anyone considering KPV should do so only with a knowledgeable prescriber and routine follow-up.

Is KPV right for you now?